Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6423 · 1 trial · 1 indication
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
The primary objectives of this study are to assess the safety and tolerability of single and multiple ascending dosage levels of AZD6423 versus placebo in healthy volunteers.
| Arm | Type | Description |
|---|---|---|
| Experimental: AZD6423 | EXPERIMENTAL | Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo. |
| Placebo to match AZD6423 | PLACEBO_COMPARATOR | Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| AZD6423 | DRUG | Drug: AZD6423 Single or Multiple doses via infusion. |
| Placebo | DRUG | Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion |
Inclusion Criteria: 1. Subjects must understand the nature of the study and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any study-specific procedures. 2. All male subjects who are biologically capable of having children must agre...
AZD6423 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease or condition it is intended to treat has not been disclosed, and the program is in early-stage clinical development.
AZD6423 is made and developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the sponsor of the Phase 1 study conducted for this compound.
AZD6423 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. Because only early-stage testing has been conducted, AZD6423 is investigational and has not been approved by the FDA for any indication.
AZD6423 was evaluated in a single Phase 1 trial, NCT01926366, titled AZD6423 SAD/MAD Study in Healthy Volunteers. The trial was a randomized, double-blind, placebo-controlled study that enrolled 175 healthy adult volunteers in the United States and has been completed.
The AZD6423 Phase 1 trial, NCT01926366, used a single ascending dose and multiple ascending dose design. It was randomized, double-blind, and placebo-controlled, enrolling 175 healthy volunteers of all sexes in the United States. The study has been completed.